VIDAC Pharma Ltd.
Sector: Pharma - Therapeutics
Medical Field: Oncology
Technological Field: Ethical Pharmaceuticals
Year Established: 2012
VIDAC Pharma Ltd. is a privately held company specializing in research and development of ethical pharmaceuticals in the fields of oncology and dermatology (skin cancer). The company develops an innovative new class of anti-cancer drugs. VIDAC’s small-molecule drugs utilize a breakthrough mechanism-of-action which selectively targets the metabolism of cancer cells without affecting normal tissue.
The lead drug, VDA- 1102, is a first-in-class treatment for the non-melanoma skin cancers, including Actinic Keratosis and Squamous Cell Carcinoma. This treatment could be revolutionary, and will enhance the quality of life for those who suffer from these cancer diseases. This drug will start Phase 2 clinical trials in human patients in early 2016. A second drug, VDA-1214, which is in preclinical development targets systemic tumors (such as lung cancer and breast cancer) utilizing the same innovative mechanism of action.